David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.
David M. O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at the Ohio State University (OSU) College of Medicine, as well as the director of the Division of Gynecologic Oncology, director of Clinical Research in Gynecologic Oncology, and co-director of the Gynecologic Oncology Phase I Program at The OSU Comprehensive Cancer Center–James, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.
During the 2021 SGO Virtual Annual Meeting on Women’s Cancer, findings from the study demonstrated significantly improved efficacy with the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) vs physician’s choice chemotherapy in patients with advanced endometrial cancer who received prior platinum-based chemotherapy.
The results demonstrated a median overall survival of 18.3 months with pembrolizumab/lenvatinib vs 11.4 months with chemotherapy in all-comers. The median PFS was 7.2 months and 3.8 months, respectively.
The overall response rate was 31.9% with pembrolizumab/lenvatinib compared with 14.7% with chemotherapy, with complete response rates of 6.6% and 2.6%, respectively. The median duration of response was 14.4 months with the combination vs 5.7 months with chemotherapy.